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Abstract
Background: Rebamipide is a gastroprotective agent with promising results against gastric damage induced by
non-steroidal anti-inflammatory drugs. The present study evaluated if rebamipide protects against naproxen-induced
gastric damage in healthy volunteers. Changes in gastric PGE2 tissue concentration were also evaluated.
Methods: After a preliminary endoscopy to rule out previous gastric macroscopic damage, twenty-four healthy
volunteers of both sexes were divided into 2 groups. One group received sodium naproxen 550 mg b.i.d. plus placebo
for 7 days, while the other group received sodium naproxen 550 mg b.i.d. plus rebamipide 100 mg b.i.d. At the end of
treatment, a new endoscopy was performed. Gastric macroscopic damage was evaluated by the Cryer score and by
the modified Lanza score. The primary outcome measure of the trial was the macroscopic damage observed in each
treatment group at the end of treatment. Biopsies were collected at both endoscopies for PGE2 quantification and
histopathological analysis (secondary outcomes). Tissue PGE2 was quantified by ELISA. The randomization sequence
was generated using 3 blocks of 8 subjects each. Volunteers and endoscopists were blind to whether they were
receiving rebamipide or placebo.
Results: All recruited volunteers completed the trial. Sodium naproxen induced gastric damage in both groups. At the
end of the study, median Cryer score was 4 in both groups (Difference = 0; 95%CI = −1 to 0; p = 0.728). In the placebo
group, the mean tissue PGE2 concentration was 1005 ± 129 pg/mL before treatment and 241 ± 41 pg/mL after
treatment (p < 0.001). In the rebamipide group, the mean tissue PGE2 concentration was 999 ± 109 pg/mL before
treatment, and 168 ± 13 pg/mL after treatment (p < 0.001). There was no difference in mean tissue PGE2 between the
two groups (difference = 5; 95%CI from −334.870 to 345.650; p = 0.975). No significant change was observed at the
histopathological evaluation, despite the evident macroscopic damage induced by naproxen.
Conclusion: Rebamipide does not protect against naproxen-induced gastric damage in healthy volunteers.
Trial registration: ClinicalTrials.gov, NCT02632812. Registered 14 December 2015.
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Background
Naproxen and other non-selective non-steroidal anti-
inflammatory drugs (NSAIDs) induce gastrointestinal
(GI) adverse events ranging from dyspepsia to upper and
lower GI tract ulcers [1–3]. Naproxen 660 – 1000 mg
per day administered for 2 to 14 days is used as a model
for NSAID-induced gastroduodenal damage in healthy
volunteers [4–8].
Rebamipide has been described as a GI mucosal pro-
tector agent with promising results in prophylaxis and
treatment of GI ulcers caused by NSAIDs, H. pylori or
endoscopic submucosal dissection [9–15]. Results from
animal studies have suggested that the protective effects
of rebamipide are attributable to stimulation of prosta-
glandin (PG) synthesis [16, 17]. In healthy volunteers,
concomitant administration of rebamipide 100 mg with
ibuprofen 600 mg t.i.d. for 7 consecutive days resulted in
a mean gastric damage score of 1.3 ± 1.0, which was
significantly lower than that of the control group (mean
score of 2.9 ± 1.7), as assessed by the modified Lanza
score (p = 0.032) [10]. In patients with rheumatic disease
rebamipide 100 mg b.i.d. also showed a protective effect
against NSAID-induced gastric damage [18].
The present study evaluated whether rebamipide could
provide a protective effect against naproxen-induced
gastric damage in healthy volunteers.
Methods
Volunteers
Volunteers of both sexes aged 18 years old or older
without any significant cardiac, hepatic, renal, pulmon-
ary, neurological, gastrointestinal or hematological dis-
eases, as determined by their medical history, physical
examination, and routine laboratory tests (hematology,
blood biochemistry, urine analysis and fecal occult blood
test), were invited to participate in this double-blind,
randomized, parallel placebo-controlled phase II single-
center trial. All subjects tested negative for hepatitis B
and C (except for serologic scar), as well as HIV I and II,
and were instructed to abstain from taking any medica-
tion including over-the-counter medication for 2 weeks
prior to and during the study period. Pregnancy was an
exclusion criterion. All women enrolled had negative β-
HCG. All volunteers were informed about the aim and
risks of the study by the clinical investigator and they all
signed a written informed consent statement before enter-
ing the study. The study was performed according to the
2008 revised Declaration of Helsinki for bio-medical re-
search involving human subjects and the 1996 rules of
Good Clinical Practices. The study protocol was approved
by the Committee of Research Ethics of the University of
Sao Paulo, Sao Paulo, Brazil, on 26 November 2014
(before the initiation of the study procedures), and the
study is registered at ClinicalTrials.gov, ID NCT02632812.
After performing a preliminary gastroduodenal endos-
copy at the Vera Cruz Hospital (Campinas, Brazil) to
rule-out prior macroscopic upper GI damage in the
subjects, twenty-four healthy volunteers (12 men) were
enrolled in the study. Other exclusion criteria were:
achlorhydria (pH > 6.5); positive fecal occult blood test;
drug abuse, including alcohol or tobacco.
Treatment
Volunteers were randomly divided into 2 groups: group
A received 550 mg of sodium naproxen (Flanax® - Bayer)
plus an effervescent placebo (Biolab Indústria Farmacêu-
tica Ltda.) diluted in 200 mL of water b.i.d. for 7 con-
secutive days; group B received 550 mg of sodium
naproxen (Flanax® - Bayer) plus 100 mg of effervescent
rebamipide (Biolab Indústria Farmacêutica Ltda.) diluted
in 200 mL of water b.i.d. for 7 consecutive days. The
randomization sequence was determined using the
randomization generator available at www.randomiza-
tion.com, using 3 blocks of 8 subjects each. Volunteers
were blind to whether they were receiving rebamipide or
placebo. To assure adherence, the drugs were adminis-
tered by a member of the research team (also blind to
treatment allocation) early in the morning and late in
the evening for the whole duration of the study. A
pharmacist was responsible for labeling treatments as A
or B, and for breaking the code at the end of the study.
Volunteers were required to be fasted in the morning
and were only allowed to eat at least 2 h after adminis-
tration of medications. In the evening, volunteers were
required to be at least for 2 h without ingestion of food,
and were also asked to avoid eating for the following 2 h
after the dose.
Adverse reactions were individually evaluated. Causal-
ity relationship to the treatment was assessed with the
aid of the Karch & Lasagna algorithm [19]. The necessity
of interruption of treatment or specific therapy was indi-
vidually assessed by the Principal Investigator depending
on the severity of the reaction and the causality relation-
ship to the treatment.
Gastrointestinal damage evaluation
Gastroduodenal endoscopy was performed before the
start of the study and in the morning of the 8th day of
treatment in all volunteers. Exams were performed by a
single endoscopist. The primary outcome measure of the
trial was the macroscopic damage observed in each
treatment group at the end of treatment. The number of
mucosal erosions after treatment was counted and
macroscopic mucosal injury scored according to Cryer
[20] and to the modified Lanza score (MLS; Table 1)
[9, 21]. Gastroduodenal ulcers were classified according
to the Sakita-Miwa classification. Additionally, a second
endoscopist retrospectively evaluated the exams, blind to
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the scores given by the first endoscopist. If there was any
difference between the score given by the two endoscopists,
the final score would be the mean value of the two num-
bers. Both endoscopists were blind to treatment group allo-
cation of volunteers. In each exam 3 biopsies were
collected from the gastric antrum and 3 from the gastric
corpus for PGE2 quantification. Samples were immediately
washed in phosphate buffer saline at pH 7.4 and stored in-
dividually in a dry Eppendorf tube and kept at −20 °C
until analysis. Another 2 biopsies from each stomach re-
gion (4 total) were collected at each endoscopic proced-
ure for histological analysis. Volunteers were questioned
about GI symptoms at every dose. Changes in gastric
PGE2 concentration, histopathological characteristics
and GI symptoms at the end of the study compared to
baseline were evaluated as secondary outcome measures.
A more detailed questionnaire about GI symptoms such
as heartburn, abdominal pain, fullness, nausea, vomiting,
blood in stools or others was completed before receiving
the first dose and at the last day of treatment. In the
questionnaires, when any symptom was reported, the vol-
unteer was asked to describe the intensity and frequency
of the symptom over the previous 7 days. Routine labora-
tory tests were repeated at the end of treatment, includ-
ing fecal occult blood test.
PGE2 quantification
Tissue PGE2 concentration was quantified by enzyme-
linked immunosorbent assay (ELISA) using Cayman
Chemical Monoclonal Prostaglandin E2 EIA Kit (item
number 514010). Briefly, biopsies from the gastric an-
trum and corpus collected in both endoscopic proce-
dures were weighted and homogenized individually for
20 s by a Polytron in 1 mL of Na3PO4 buffer solution
(pH = 7.4). Aliquots of 200 μL of the homogenate were
placed in a dry bath at 37 °C for 20 min and then centri-
fuged at 20,800 g for 30 s. Supernatant (150 μL) was col-
lected and diluted 1:100 (v/v) to be used in the ELISA.
Each aliquot was assayed in duplicate and final PGE2
concentrations were adjusted for initial sample mass.
Data are displayed as mean ± SEM. The person respon-
sible for the quantification of PGE2 was blind to treat-
ment group allocation of volunteers.
Histopathological evaluation
Biopsies from gastric antrum and corpus were immedi-
ately put in formaldehyde after collection. Samples were
stained in hematoxylin and eosin for characterization
and graded according to a score described in Table 2.
Giemsa stain was used to diagnose H. pylori infection.
The pathologist was also blind to treatments.
Statistical analysis
For evaluation of statistical difference of tissue PGE2 be-
tween treatments, a t-test was performed. A paired t test
was used to compare tissue PGE2 before and after treat-
ments within each group. Endoscopic and histopatho-
logical scores between treatment groups were compared
using the Mann–Whitney U-test. Gastrointestinal symp-
toms after treatments were compared by Fisher’s exact
test. A p value <0.05 was considered significant. The
sample size planned for the study was 24 volunteers of
both sexes. This number was chosen based on the gas-
troprotective effects of rebamipide previously reported
[9]. The calculation considered the Mann–Whitney U
test analysis of the reported data on gastroduodenal
damage scoring by MLS. The effect size observed
(difference between treatments) was 67 % (median
score after treatment of 3 and 1, in the placebo and
rebamipide groups, respectively). Given a power of
80 % and a 0.05 chance of type 1 error, the original
sample size estimation was 10 volunteers per group.
The final number of 12 volunteers per group was
chosen considering a 20 % rate of drop-out. Other
studies with rebamipide in healthy volunteers also
used similar sample sizes [10, 15].
Results
All 24 volunteers enrolled completed all procedures of the
study. The median age of men was 24 years (range 18 –
49 years), mean weight was 75.7 kg (61.0 – 97.0 kg), mean
height was 175 cm (152 – 186 cm), and mean body mass
index was 24.8 kg/m2 (20.2 – 28.7 kg/m2). Women had a
Table 1 Cryer and modified Lanza scores according to
gastroduodenal mucosal injury
Score Cryer score Modified Lanza score
0 Normal or erythema No hemorrhage or erosion
observed
1 Any amount of submucosal
hemorrhage or edema without
erosions.
One or two hemorrhages or
erosions observed in one
gastric area.
2 1 erosion ± submucosal
hemorrhage or edema.
Three to five hemorrhages or
erosions observed in one
gastric area.
3 2–4 erosions ± submucosal
hemorrhage or edema.
Hemorrhages or erosions
observed in two gastric areas;
six or more hemorrhages or
erosions observed in one
gastric area, with the total
number not exceeding ten in
the entire stomach.
4 5 or more erosions and/or a
single ulcer ± submucosal
hemorrhage or edema.
Hemorrhages or erosions
observed in three or more
gastric areas; eleven or more
hemorrhages or erosions
observed widely in the entire
stomach.
5 Multiple ulcers ± submucosal
hemorrhage or edema.
Ulcer.
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median age of 24.5 years (range 20 – 42 years), mean
weight was 69.5 kg (54.0 – 83.0 kg), mean height was
164 cm (153 – 170 cm), and mean body mass index was
25.9 kg/m2 (20.7 – 28.7 kg/m2). Three volunteers (two
men) were not allowed to enroll in the study because of
gastric damage observation in the preliminary endoscopy.
There was agreement between the endoscopists on the
scores of all exams. Endoscopic findings and scores for each
volunteer using the macroscopic scoring systems are sum-
marized in Table 3. The median Cryer score was 4 in
both placebo and rebamipide groups (Difference = 0;
95%CI = −1 to 0; p = 0.728). The median MLS was 4
in the placebo group and 3.5 in the rebamipide group
(Difference = 0.5; 95%CI = −2 to 1; p = 0.822). In the
placebo group 2 volunteers (16 %) presented GI ul-
cers (1 ulcer each), while 4 volunteers (32 %) in the
rebamipide group had ulcers (p = 0.320). Figure 1a
and b illustrate the macroscopic aspect of the gastric
mucosa of volunteer 24 in the rebamipide group be-
fore treatment and at the end of the study.
The incidence of GI symptoms in each treatment
group is displayed in Table 4. Individual data regarding
Table 2 Histhopathologic grade score developed for
microscopic injury evaluation
Score Findings
0 Normal gastric mucosa or mild chronic inflammation
1 Chronic gastritis without activity
2 Chronic gastritis with activity on antrum
3 Chronic gastritis with activity on the body
4 Chronic gastritis with activity on antrum and on the body
Table 3 Summary of findings in the endoscopic procedure at the end of treatments
Volunteer
#
Treatment Scores before
treatment
Cryer
Score
Lanza
Score
Antrum Duodenum Other
2 Placebo 0 3 2 4 erosions
5 Placebo 0 2 1 1 erosion + submucousal
hemorrage
7 Placebo 0 4 4 >20 erosions
8 Placebo 0 4 5 2 erosions + 1 ulcer
(Sakita A2)
10 Placebo 0 4 4 >10 erosions
12 Placebo 0 4 5 10 erosions + 1 ulcer
(Sakita A2)
14 Placebo 0 4 2 5 erosions
16 Placebo 0 4 4 20 erosions
17 Placebo 0 4 4 10 erosions 3 erosions
18 Placebo 0 4 4 10 erosions
19 Placebo 0 4 4 10 erosions
23 Placebo 0 4 4 10 erosions
1 Rebamipide 0 4 4 20–25 erosions
3 Rebamipide 0 4 4 10 erosions
4 Rebamipide 0 4 5 10 erosions 1 ulcer
(Sakita A2)
6 Rebamipide 0 3 1 2 erosions + erythema
9 Rebamipide 0 3 2 3 erosions
11 Rebamipide 0 3 3 2 erosions Submucousal hemorrhage in
gastric fundus
13 Rebamipide 0 5 5 Small erosions + 2 ulcers
(Sakita A2)
15 Rebamipide 0 4 2 5 erosions + erythema
20 Rebamipide 0 3 2 4 erosions
21 Rebamipide 0 4 5 Pylorus with edema and 1 ulcer
(Sakita A2)
22 Rebamipide 0 3 2 3 erosions
24 Rebamipide 0 5 5 10 erosions + 4 ulcers
(Sakita A2)
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GI symptoms is available in Additional file 1: Table S1.
There were no statistical differences between treatment
groups at the end of the study. All fecal occult blood
tests were negative at the end of treatment.
PGE2 quantification
In the placebo group, the mean tissue PGE2 concentra-
tion was 1005 ± 129 pg/mL before treatment, and 241 ±
41 pg/mL after treatment (difference = 764; 95%CI from
477 to 1051), which corresponded to a mean inhibition
of PGE2 synthesis of 76.0 % (p < 0.001). In the rebami-
pide group, the mean tissue PGE2 concentration was
999 ± 109 pg/mL before treatment, and 168 ± 13 pg/mL
after treatment (difference = 831.5; 95%CI from 612 to
1051), a mean inhibition of 83.2 % (p < 0.001). There
was no difference between the two groups in PGE2
tissue concentration before treatments (difference = 5;
95%CI from −334.870 to 345.650; p = 0.975). The indi-
vidual PGE2 concentration found for each volunteer be-
fore and after treatment is available in Additional file 2:
Table S2.
Histopathological evaluation
At the initial endoscopic procedure, median histopatho-
logical scores were 1 in both groups (Difference = 0;
95%CI = −3 to 1; p = 0.582). At the end of the study, me-
dian histopathological scores were also 1 in both groups
(Difference = 0; 95%CI = −1 to 1; p = 0.997). At the initial
endoscopy, 5 volunteers in each group were H. pylori
positive. At the end of treatments, 6 subjects in each
group were H. pylori positive. The individual histopatho-
logical score for each patient as well as H. pylori status
before and after treatment is available in Additional file
3: Table S3.
Discussion
The present study did not find any evidence of a gastro-
protective effect of rebamipide on naproxen-induced
gastroduodenal damage as assessed by endoscopic
macroscopic evaluation. This result differs from previous
findings, in which rebamipide treatment resulted in less
severe gastric damage induced by NSAIDs [9, 10, 15].
One possible explanation for the different results found
in the present work is that naproxen was more aggres-
sive than others models of NSAID-induced gastric dam-
age. To evaluate this possibility, previously published
data was further analyzed. Treatment with indomethacin
at 75 mg/day without rebamipide for 7 consecutive days
resulted in a median MLS of 3. When treatment was as-
sociated with rebamipide 100 mg t.i.d., median MLS was
1 [9]. Treatment with ibuprofen 1800 mg/day for 7 con-
secutive days without rebamipide resulted in a median
MLS of 3. When volunteers received rebamipide con-
comitantly with ibuprofen, median MLS was 2 [10]. By
performing the Mann–Whitney U-test to compare MLS
scores from the placebo group in the present study to
those found in the placebo groups of the previously
mentioned studies, no difference in gastric lesion scores
among these 3 models of NSAID-induced gastric dam-
age was observed (indomethacin vs. naproxen, p = 0.475;
ibuprofen vs. naproxen, p = 0.343; indomethacin vs. ibu-
profen, p = 1.0). However, since the characteristics of
Fig. 1 Photographic documentation of the endoscopic procedure in a
volunteer in the rebamipide group (a) before and (b) after treatment
Table 4 Incidence of gastrointestinal symptoms
Gastrointestinal
symptom
Placebo (n = 12) Rebamipide (n = 12) P value
Before After Before After Before After
Any 3 5 5 3 0.67 0.33
Abdominal pain 2 3 3 2 0.50 0.50
Heartburn 2 2 3 1 0.50 0.50
Nausea 1 2 1 1 0.76 0.50
Intestinal cramps 0 1 1 0 0.50 0.50
Fullness 1 0 0 0 0.50 1.00
Incidence of gastrointestinal symptoms in each treatment group before the
beginning and at the end of the study. P value was calculated comparing
incidence of symptoms between placebo and rebamipide groups before and
after treatments by Fisher’s exact test
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volunteers enrolled in the aforementioned studies are
very different from those of the present study and trials
designs are not the same, final conclusions cannot be
drawn from these statistical analyses.
Since all the aforementioned studies evaluated Japa-
nese or Korean subjects [9, 10, 13, 15, 18], population
characteristics may have influenced the results. Higher
gastric pH is known to be a protective factor in NSAID-
induced gastric damage. The incidence of hypochlorhy-
dria in the Japanese population is higher than in western
countries, affecting more than 40 % of individuals over
50 year olds in Japan [22], while in the Unites States the
incidence varies from 8 % in young adults to 11 % in the
elderly [23, 24]. The higher gastric pH might facilitate
the observation of the protective effect of rebamipide re-
ported in Asian individuals. Another possibility for dif-
ferences in rebamipide effects in NSAID-induced gastric
damage is the genetic and dietary characteristics of the
populations evaluated in each study.
One difference of the present study is that the daily dose
of rebamipide was 200 mg, while most previous reports
treated volunteers with 300 mg of rebamipide per day
[9–15, 25, 26]. However, rebamipide at 200 mg/day in
patients with rheumatic disease showed a protective effect
in NSAID-induced gastroduodenal mucosal injury [18]. It
is unlikely that a reduction in 33 % of the dose would
abolish the supposed effect of rebamipide. A lower dosage
of rebamipide was chosen due to safety concerns. Most of
the safety data about rebamipide comes from studies in
Asian populations. This is the first time a study evaluated
effects of rebamipide in a Brazilian population.
Increased PG synthesis was previously suggested as a
possible mechanism for mucosal protection of rebami-
pide [16, 17]. If so, rebamipide should not have a pro-
tective effect in NSAID-induced gastric damage through
modulation of PG synthesis, since NSAIDs block the ac-
tivity of cyclooxygenases.
In the present study, no significant histopathological
change of the gastric mucosa was seen at the end of
treatment in neither groups, despite the clear aggressive-
ness of naproxen observed on macroscopy. These results
confirm previous reports that identified the histological
features characteristic of NSAID users only in a subset
of patients, and that microscopic findings do not correl-
ate with macroscopical damage [27, 28]. This may reflect
that the histological parameters used lack sufficient
sensitivity or else, the mechanism responsible for the
appearance of erosions and ulcers is independent of the
degree of inflammation.
Conclusion
Rebamipide 200 mg/day does not protect against
naproxen-induced gastroduodenal damage in healthy
volunteers.
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